Clinical data | |
---|---|
Pronunciation | /məˈrɒpɪtænt/ mə-ROP-i-tant |
Trade names | Cerenia, Prevomax, Vetemex |
Other names | (2S,3S)-2-Benzhydryl-N-(5-tert-butyl-2-methoxybenzyl) quinuclidin-3-amine, maropitant citrate (USAN US) |
AHFS/Drugs.com | International Drug Names |
License data |
|
Routes of administration | Oral, subcutaneous, Intravenous transdermal |
Drug class | Antiemetic |
ATCvet code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Oral: 20–30% dogs, 50% cats SQ: 90% (both) |
Protein binding | 99.5% |
Metabolism | Liver (CYP3A12 and CYP2D15) |
Metabolites | CJ-18,518 |
Elimination half-life | 6–8 hours (SQ) |
Duration of action | 24 hours (SQ) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C32H40N2O |
Molar mass | 468.685 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Maropitant (INN;[2] brand name: Cerenia, used as maropitant citrate (USAN), is a neurokinin-1 (NK1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs[3][4] and in 2012, for cats.[5]
Maropitant has mild pain-relieving, anti-anxiety and anti-inflammatory effects.[medical citation needed]